Loading clinical trials...

Oral Nadolol for the Treatment of Adults With Mild Asthma | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Oral Nadolol for the Treatment of Adults With Mild Asthma

An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma

NCT00670267•Invion, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pre-bronchodilator FEV1 80% or greater than the predicted value.
•PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
•Blood Pressure ≥ 100/65mm Hg.
•Pulse rate ≥ 60 beats/min.
•No significant health issues.
•Non-smoker or X-smoker \< 10 pack/year.

Exclusion Criteria

•History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
•Currently diagnosed with chronic obstructive pulmonary disease (COPD).
•Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.

Locations (1)

Baylor College of Medicine

Houston, Texas, United States

Key Dates

Start Date

January 1, 2007

Primary Completion Date

May 1, 2009

Completion Date

June 1, 2009

Last Updated

May 11, 2016

Enrollment

ACTUAL participants

Conditions

Asthma

Interventions

nadolol

DRUG

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

RECRUITINGPHASE2

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 11, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Oral Nadolol for the Treatment of Adults With Mild Asthma

Inclusion Criteria

Exclusion Criteria

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma